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ABSTRACT 
 
Background: Immediate-release (IR) quetiapine has been used to treat schizophrenia since 1997, despite all the 
principal placebo-controlled trials suffering from severe rates of missing outcome data (>50%), making their 
results difficult to interpret. New studies with relatively lower rates of drop-out have since been published.  
 
Aims: Our objectives were; (1) to assess the efficacy and adverse effects of quetiapine IR for schizophrenia, 
with consideration of outcome quality and clinical meaningfulness of results; (2) to examine the potential impact 
of missing data on the main efficacy findings.  
 
Method: We conducted a systematic review and meta-analysis of randomised controlled trials comparing 
quetiapine IR to placebo (or subtherapeutic dose in relapse prevention trials) for the acute and longer term 
treatment of schizophrenia. Primary outcomes were change in PANSS-rated overall symptoms and response 
rates (≥50% improvement in PANSS scores). We examined whether trials with severe drop-out (≥50%) had 
attenuated effect sizes and assessed the impact of making different assumptions about the outcome of those who 
left early. 
 
Results: Our search identified 15 relevant trials, 11 of which assessed short-term efficacy (N=2259; 2-12 
weeks). We obtained data for 2 unpublished trials, which together provided the first 12-week data for this drug, 
and the first data on self-reported quality of life. Previous research suggests patients require a mean reduction in 
PANSS total scores of at least 11 points to feel minimally better, whereas raters require at least 15 points. We 
found quetiapine IR has a Weighted Mean Difference (WMD) of 6.5 points (k=11; 95% Confidence Interval 
[CI] -8.9, -4; Standardised Mean Difference [SMD] -0.33, 95% CI -0.46, -0.21). The effect was not robust to 
changing assumptions about the outcome of the large number of people who left these trials early. Longer 
duration trials reported larger mean differences favouring quetiapine IR. Approximately 21 people needed to 
take quetiapine IR for one to experience at least a 50% improvement in PANSS scores (95% CI 13, 63). 
Response rates were smaller in more recent trials. No difference between quetiapine IR and placebo was 
observed on participant-reported quality of life (k=2; SMD 0.11, 95% CI -0.15, 0.36), according to previously 
unpublished data. Long-term quality of life data from two RCTs remains unpublished. Quetiapine IR caused 
sedation (NNH 9, 95% CI 7, 13) and clinically significant increases in weight (WMD 1.8kg, 95% CI 1.1, 2.4; 
SMD 0.64, 95% CI 0.43, 0.85; NNH 13, 95% CI 9, 23), but no extra-pyramidal effects were observed.  
 
Conclusions: The original immediate release version of quetiapine has a small effect on overall psychotic 
symptoms over 2-12 weeks. Although larger benefits were observed in longer trials, the overall differences did 
not reach criteria for clinically significant change and were not robust to changing assumptions about the 
outcome of participants who left early. The probability of experiencing much improvement in symptoms was 
considerably smaller than the probability of clinically significant weight-gain or marked sedation.   
 
Funding: There was no financial funding for this work. 
 
Key words: Quetiapine, placebo, antipsychotics, meta-analysis, schizophrenia, psychosis. 
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Introduction 
 
Quetiapine is a widely prescribed antipsychotic.(1) First manufactured by Astrazeneca, it was initially 
introduced for the treatment of schizophrenia and non-affective psychosis in the late 1990s, but is now licensed 
in several countries for the treatment of bipolar disorder and other conditions. The original immediate-release 
(IR) version was the third most frequently prescribed antipsychotic in the UK from 2004 to 2007 and, by 2008, 
had been taken by over 25 million people world-wide.(2) The patent for quetiapine IR expired in March 2012, 
and the generic version is now comparable in cost to haloperidol, leading to considerable cost-savings. Although 
older reviews of comparative and placebo-controlled trials have concluded it is an effective treatment for 
schizophrenia and non-affective psychosis, (3, 4) these were based on a limited number of trials which suffered 
from severe attrition. The Cochrane review, for example, noted that most of the original placebo-controlled 
studies were severely compromised by missing outcome data, and that their results were therefore “impossible 
to interpret with confidence”.(3) Three of the 4 included studies were missing over 50% of their 6-week 
outcome data, and the remaining study had only 12 participants. In each case the outcomes of those leaving 
early were estimated by the method of carrying their last available observation forward (LOCF), an imputation 
strategy now regarded as unreliable.(5)  
 
In their 2009 review, Leucht and colleagues found that, overall, second-generation antipsychotics had a 
moderate effect on symptoms (Hedges’s g = 0.51).(4) However they suggested that the high drop-out in these 
studies may have attenuated the drug-placebo difference. Indeed, most placebo-controlled trials have more than 
25% drop-out, and a significant number have over 50%.(6) Such high rates of missing data cannot be safely 
ignored. A recent survey by the Cochrane Schizophrenia Group found consultant psychiatrists, service users, 
carers and Cochrane researchers in agreement that trials with over 25% missing data lack credibility, (7) and 
there is largely a consensus that no statistical approach can produce reliable results when assumptions about the 
outcomes of participants carry more weight than actual observations (7, 8). Understanding the impact of missing 
data is particularly challenging if it is missing for non-random reasons which are related to outcome, as may be 
the case for antipsychotic trials. (9) The development of a sustained release version of quetiapine (quetiapine 
XR) has led to new randomised controlled trials (RCTs) comparing the IR version to placebo, some of which 
had relatively low rates of missing data. Due to the uncertainty introduced by high attrition in the older IR 
studies, we set out to perform a new systematic review and meta-analysis.  
 
We had two main objectives. Our first was to provide a comprehensive assessment of the efficacy and adverse 
effects of quetiapine IR for schizophrenia when compared to placebo, with consideration of both outcome 
quality and the clinical meaningfulness of the results, as informed by recent advances in our understanding of 
what constitutes a Minimum Clinically Important Difference (MCID)  in PANSS total scores.(10-12). Our 
second objective was to examine the potential impact of missing data on the primary outcomes. More 
specifically, we examined whether trials with high rates of missing data had smaller effect sizes (4) and we used 
a recently published approach to examine the impact on our efficacy estimates of changing assumptions about 
the likely outcomes of the high numbers of people who leave these trials early.(13)  
 
Method 
 
Search 
Our search strategy and protocol detailing our inclusion and exclusion criteria are provided in a supplementary 
file. Two researchers independently searched publication databases, clinical trial registries and previous reviews 
for RCTs where participants with a schizophrenia diagnosis or early psychosis were randomly allocated to 
receive double-blind treatment with either placebo or quetiapine IR. No pre-specified limits were placed on 
study duration. 
 
Data extraction and outcomes 
Two reviewers independently extracted data from each study, using data extraction forms. We attempted to trace 
missing summary data by contacting first authors or the study sponsor. Our primary outcomes were the average 
reduction in total scores on the Positive and Negative Syndrome Scale (PANSS) at study endpoint or, if not 
available, Brief Psychiatric Rating Scale (BPRS) and the numbers of people achieving an important clinical 
response. We defined the latter as ≥50% reduction in PANSS / BPRS scores.(14) When these were not reported 
or provided, we imputed them from means and SDs using the validated method of Furukawa and colleagues 
(15) (see ‘changes from protocol’ section in the supplementary file).  
 
Our secondary efficacy outcomes included relapse, positive symptoms, negative symptoms, depression, quality 
of life and needing additional antipsychotic medication or sedatives. We also examined the numbers leaving 
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early for any reason, need for hospital care and functioning. For adverse effects, we looked at use of 
antiparkinson medication, extrapyramidal side-effects, drop-out due to adverse events, sedation, total number of 
drug-attributable adverse events, insomnia, weight-gain and weight-loss. 
 
We used a strict intention-to-treat (ITT) analysis for dichotomous outcomes, using the total numbers randomised 
to each group as the denominator in each case. Where possible, we assumed those leaving early or otherwise 
unaccounted for had an unchanged outcome from randomisation, but carried out sensitivity analyses to test this. 
Data incorporating last-observation carried forward (LOCF) assumptions were used only when there was no 
alternative. 
 
We also wished to use a strict ITT analysis for continuous data, but expected to be limited to summary data 
derived from smaller samples excluding early drop-outs or those without at least one post-baseline assessment. 
For all outcomes, we intended to use summary data based on the mixed-model repeated measures (MMRM) 
imputation method, followed by LOCF or observed case (OC) data if not available. Missing standard deviations 
(SDs) were, where possible, calculated from t-values, p-values, standard errors or confidence intervals.(16) If no 
variance parameters were reported for a particular study, we imputed SDs using the median SD of the other 
studies. Based on previous studies, (4, 17) we planned to use data from study arms where participants received 
an optimal dose of >250mg. However we carried out a sensitivity analysis excluding doses of <400mg, as per 
the recent International Consensus on Antipsychotic Dosing (18) and recent Leucht group analysis.(19)  
 
Meta-analytic calculations 
For continuous data, we calculated the Hedges’s g standardised mean difference (SMD) using Comprehensive 
Meta-Analysis Version 2. For the primary analysis of 2-12 week study endpoint data, we converted BPRS 
means and SDs to PANSS means and SDs using recently published conversion charts (PANSS total scores = 
~1.538 x BPRS total scores) (20) thus allowing us to also present the unstandardized weighted mean difference 
(WMD) in PANSS total scores for all the studies combined. When a trial had two or more relevant arms, we 
combined the data following procedures in the Cochrane Handbook.(16)  
 
For binary data, we calculated the relative risk (RR) of the unfavourable outcome, together with 95% confidence 
intervals, as well as the absolute risk difference (RD) and numbers needed to treat (NNT) or harm (NNH). If a 
trial had eligible binary data from two or more active treatment arms, we combined these into one. We used a 
random-effects analysis for all outcomes. For the primary outcomes we also performed a sensitivity analysis 
using fixed-effects, but not if heterogeneity was moderate or more, defined as an I2 statistic of ≥40%.(16)  
 
Assessing impact of missing data 
We tested the hypothesis that trials with severe rates of missing data (≥50% at endpoint) had smaller drug-
placebo differences on our primary outcomes than trials with less severe rates (<50%). The 50% cut-off was 
chosen because it marks the point at which estimated data carries more weight than actual observations, and 
because NICE, the Cochrane Schizophrenia Group and others often exclude trials with this degree of missing 
data from their reviews. (6, 21, 22) We also wished to compare studies with <25% and ≥25% attrition at 
endpoint,(7) but we were unable to do so because no 6-12 week studies had <25% attrition.  
 
When observed case data were available, we were also able to examine the impact of missing data on the 
primary outcome by imputing values for those who left the trial early, using new guidelines provided by 
Ebrahim and colleagues.(13) Their method involves testing whether the overall treatment effect is robust under 
four increasingly more conservative strategies – two of which we applied here. Strategy 1 is non-extreme and 
involves replacing missing data in both arms of each trial with the observed case mean of the control arm. 
Strategy 2 is more conservative yet plausible, and uses the highest observed control arm mean to replace 
missing control arm data, and the lowest observed intervention arm mean to replace missing intervention arm 
data. For both approaches, we imputed the missing data treatment and placebo SDs with the median SD of the 
control arms of all the included trials, as recommended.(13)  
 
Analysis of clinical significance 
The Minimum Clinically Important Difference (MCID) has been defined by Jaeschke and colleagues as: “the 
smallest difference in a score in the domain of interest which patients [or providers] perceive as beneficial and 
which would mandate in the absence of troublesome side-effects and excessive cost, a meaningful change in the 
patient’s management”.(11, 23) An analysis of data from 14 antipsychotic trials (10) (N=5970) found a rater-
determined MCID on the PANSS of roughly 15 points, a criterion which has since been replicated by separate 
analyses of two large non-industry effectiveness trials (N=1650).(11, 12) Data from a large naturalistic study 
(N=398) suggested a lower criterion of 10 points, (24) which is similar to the patient-rated MCID of 11 points 
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derived from the CATIE trial.(12) We tested the validity of these definitions by comparing them to the median 
of mean changes the included trials were designed to detect. We assumed that trial sponsors had provided 
enough resources to detect with adequate power what they regarded, a priori, as the smallest difference between 
the groups that is important to detect.(25)  
 
Risk of bias and study quality 
Two raters independently assessed both study-level risk of bias with the Cochrane Collaboration Risk of Bias 
tool, (16) and outcome quality using the GRADE approach.(26) Further details on methods and ratings are 
provided in a supplementary file. We tested for publication bias using funnel plots for the PANSS/BPRS total 
score effect sizes (Hedges’s g) of all studies. Ratings of bias and quality were used to inform interpretation of 
reliability and magnitude of effects. 
 
Pre-registration of review protocol and subsequent changes 
The review protocol was registered in advance with PROSPERO (International Prospective Register of 
Systematic Reviews). Subsequent changes, in addition to those outlined above, are detailed in the supplementary 
file. We abandoned the use of the response-rate hierarchy used by Leucht et al (4), given their recently 
expressed concerns that response rate estimates are particularly vulnerable to selective reporting bias (19), and 
used only the top of the hierarchy instead (50% or more reduction in PANSS / BPRS scores). This criteria is 
now recommended for use in studies of acutely ill, non-refractory patients (27), and we used the Furukawa et al 
method to impute this data when not reported or provided (15). This method has been recently validated using 
individual patient-level data from 16 antipsychotic trials (28), and has the additional advantage of allowing for 
the use of adjusted PANSS and BPRS total scores when calculating percentage change, thus avoiding 
underestimation of response (27). Additional changes included using meta-regression to assess the association 
between (i) study duration (measured in weeks) and (ii) year of publication on total symptoms and clinically 
significant improvement. These were conducted in STATA version 9 using the Metareg command and Knapp-
Hartung variance estimator (29). 
 
Results 
 
Search 
The process of selecting studies is detailed in Figure 1. We identified 15 relevant trials, 11 of which assessed 
short-term efficacy (N=2259). Lundbeck provided us with summary reports for two unpublished 12-week 
placebo-controlled studies, (30, 31) both of which were terminated early due to inefficacy of the investigational 
drug (bifeprunox; quetiapine IR was an active comparator in these trials). Astrazeneca, the makers of quetiapine, 
provided us with a considerable amount of additional unpublished data in relation to many of their trials. They 
decided not to provide us with the report for one unpublished long-term trial comparing therapeutic and sub-
therapeutic doses of quetiapine (32), arguing the lack of a placebo control meant it did not meet our original 
inclusion criteria. However we managed to acquire an extract detailing the main results, and other published 
summaries allowed us to partially assess risk of bias. We therefore included data from a total of 15 studies. An 
overview of included studies in provided in Table 1, and excluded studies are listed in the supplementary file, 
together with a table of trial characteristics and baseline demographics.  
 
Risk of bias and GRADE 
Table 1 also provides the main risk of bias ratings and the right-hand columns of Tables 2 and 3 provide the 
outcome quality ratings for the main primary and safety outcomes. Ratings for secondary outcomes and 
additional safety outcomes are provided in the supplementary file. Our rationale for the ratings is also provided 
in the supplementary file, alongside ratings produced by other research groups (where available). In our 
judgement, the main problem with these trials is a somewhat high risk of selective reporting bias in relation to 
secondary outcomes and adverse effects, coupled with a very high risk of attrition bias for most outcomes. We 
also judge unblinding due to sedative effects to be likely (33), and the double-blind design might not protect 
against the risk of researchers adopting a high threshold for recording effects (eg., adverse effects) where the 
desired outcome is ‘no difference’ (34). There is also evidence from documents released through legal 
proceedings in the US that Astrazeneca have historically not published all active-comparator quetiapine trials, or 
have not reported all outcomes. (35)  
 
Validation of Minimal Clinically Important Difference criterion 
Researchers and trial sponsors designed their trials to detect with adequate power a mean change in PANSS total 
scores, or equivalent, of approximately 12 points (range 9 to 15.5), which corresponds to an SMD of 0.55, and is 
similar in magnitude to the empirically derived estimate of Minimal Clinically Important Difference of 11-15 
points. (10-12).  
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Outcomes 
 
Primary efficacy outcomes (Table 2 and Figures 2-3) 
Moderate to high quality evidence suggested quetiapine IR was statistically superior to placebo from 2 to 12 
weeks in terms of reducing overall symptoms, but the effect was small (WMD -6.5 points, 95% CI -8.89, -4.00; 
SMD -0.33, 95% CI -0.46, -0.21) and the 95% confidence intervals excluded the MCID of 11-15 points. Low to 
moderate quality evidence suggested the NNT for much improvement was 21 (95% CI 13, 63). 
  
Sensitivity analyses and meta-regression 
These analyses identified a significant effect of study duration (weeks) on the effect size for total PANSS, B = -
0.04, (95% CI: -0.08, -0.01), p = .02, with a more treatment-favourable outcome associated with longer 
duration. Treatment duration did not significantly moderate the effect for treatment response, B < -0.01, RR = 
1.00 (95% CI 0.98, 1.01), p = .70. Excluding the two 2-week studies (36, 37) was associated with a marginal 
increase in average PANSS change (WMD -7.7 points, 95% CI -10.0, -5.3; SMD -0.38, 95% CI -0.50, -0.26) 
and response rates (NNT 19, 95% CI 11, 59). Year of publication did not significantly predict outcomes for total 
PANSS, B = 0.01 (95% CI -0.01, 0.04), p = .28, but there was a small association for treatment response, B = 
.01, RR = 1.01 (95% CI 1.00, 1.02), p = .01, with a less treatment favourable outcome associated with a more 
recent publication date. Meta-regression bubble-plots are provided in the supplementary file.  
 
Removing data from arms employing <400mg dose reduced the contribution made by two trials (38, 39) but this 
had little effect on the overall estimate of average change (WMD -6.3, 95% CI -8.7, -3.8; SMD -0.32, 95% CI -
0.44, -0.20) or response rates (NNT 20, 95% CI 13, 53). Excluding the adolescent study (40) also had little 
effect on estimates (WMD -6.3, 95% CI -8.9, -3.6; SMD -0.32, 95% CI -0.45, -0.19; NNT 22, 95% CI 13, 83). 
 
The impact of missing data 
Overall, the seven 2-12 week trials with less than 50% attrition had a mean PANSS advantage of -5.4 points 
(95% CI  -8, -2.9; SMD -0.29, 95% CI -0.44, -0.15) and an NNT of 42 (19, 250H), whereas the four 6-week 
studies with 50% or more attrition had a mean PANSS advantage of 9.2 points (95% CI -15, -3.4; SMD -0.39, 
95% CI -0.62, -0.17) and NNT of 13 (95% CI 7, 250). The three 6-week studies with less than 50% attrition had 
a mean advantage of 6.1 points (95% CI -9.9, -2.3; SMD -0.27, 95% CI -0.43, -0.12) and a nonsignificant NNT 
of 35 (95% CI 12, 42H).  
 
Strategy 1 of the Ebrahim approach (13) involved testing whether the overall results would be different if we 
assumed that participants who dropped out early from both groups had the same degree of change as participants 
in the control group who stayed until the end. To illustrate this, consider the Small et al trial (41). Here the mean 
change for the 49 quetiapine and 39 placebo group completers was, after conversion of BPRS to PANSS scores, 
-23.3 points (SD 17.7) and -14.9 points (SD 17.7) respectively – a between-group difference of around 8.4 
points. Carrying forward the last available scores of the 104 non-completers in this trial reduced the quetiapine 
estimate to -13.5 points (SD 24.5; N=94) and the placebo estimate to -1.5 points (SD 24.0; N=94), and increased 
the between-group difference to around 12 points. These are the figures we used in the main analysis. 
Introducing the Strategy 1 assumption that non-completers had a similar outcome to the placebo group 
completers (-14.9 points) reduced the overall estimate for the quetiapine group to -19.1 points (SD 18.2), and 
reduced the advantage over placebo to 4.2 points. We carried out the same procedure for the other 5 trials for 
which we had completer data and where no usable MMRM estimates were provided (38, 39, 42-44), and entered 
the revised estimates into the overall meta-analysis. Table 2 shows the overall advantage for quetiapine over 
placebo fell to 4.3 points (95% CI -6.5, -2; SMD -0.23; 95% CI -0.35, -0.11).  
 
Strategy 2 of the Ebrahim approach involved testing whether the overall results were robust to assuming that (a) 
quetiapine non-completers had the smallest treatment response observed and (b) placebo non-completers had the 
largest placebo response observed. In Small et al 1997, this involved assuming the 47 quetiapine non-completers 
had the same degree of response as quetiapine completers in the Lindenmayer 2008 study (-17.4 points) (39), 
and that the 57 placebo non-completers had the same degree of response as placebo completers in the Kahn 
2007 study (-23.1 points) (43). The revised quetiapine and placebo estimates were -20.4 (SD 18.2) and -19.8 
points (SD 18.3) respectively, leading to a between-group difference of 0.6 points. As shown in Table 2, 
applying Strategy 2 to the 6 trials where we had completer data reduced the overall advantage for quetiapine to 
2.7 points (95% CI -5.5, 0.2; SMD -0.15, 95% CI -0.30, 0.01). Revised forest-plots for Strategies 1 and 2 are 
provided in the online supplementary file. 
  
Publication Bias 
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We detected some asymmetry in the funnel-plot of clinically significant change, but not in relation to mean 
change in overall symptoms or most other outcomes. Funnel-plots for the primary outcomes are provided in the 
supplementary file. 
 
Secondary efficacy outcomes (Supplementary file, sections H & K)  
 
Relapse, exacerbation and need for hospital care 
There was evidence from one study suggesting quetiapine IR was effective for prevention of symptom 
exacerbation in people with early psychosis who have responded to quetiapine (45) but an unpublished study 
suggested there was no effect of therapeutic dose (300-600mg) over subtherapeutic dose (75mg) in relapse 
prevention in chronic schizophrenia.(32) The combined estimate was therefore heterogeneous (I2=87%) and not 
significant (NNT 5; 95% CI 2, 13H). Quetiapine IR was associated with a marginally reduced need for hospital 
care after 2-6 weeks (3 RCTs) (36, 37, 44) (NNT 19, 95% CI 10, 143). One trial suggested quetiapine IR had a 
small effect over 52 weeks in relation to reducing rehospitalisation due to relapse (45) (NNT 11, 95% CI 6, 143) 
but the results were not robust to changing assumptions about the outcome of those leaving early. Overall the 
relapse and rehospitalisation data were very low to low in quality. 
  
Other outcomes 
There was a small effect on positive symptoms (SMD -0.32, 95% CI -0.44, -0.20; moderate quality evidence) 
and a marginal to small effect on negative symptoms (SMD -0.21, 95% CI -0.32, -0.10; moderate quality 
evidence) over 2-12 weeks, and a marginal effect on depression over 2-6 weeks (SMD -0.13, 95% CI -0.23, -
0.02; low quality evidence). Forest-plots are provided in the supplementary file. We did not investigate whether 
these estimates were robust to missing data, but the sensitivity analyses for the primary outcome of total 
symptoms suggests this is unlikely. Those taking quetiapine IR had a marginally reduced need for additional 
sedative medication after 2-6 weeks (NNT 34; 95% CI 13, 53H; 6 RCTs), but we judged the evidence as low 
quality because of selective reporting and missing data, and no reduced need for antipsychotic medication was 
observed in the two 6-week RCTs where additional medication was not restricted (NNT 24, 95% CI 7, 19H; 
moderate quality evidence) (36, 37). 
 
Pooled self-report endpoint data from the two 12-week trials (30, 31) did not indicate any benefit of quetiapine 
IR on quality of life, as measured by the Schizophrenia Quality of Life (S-QoL) scale (SMD 0.11, 95% CI -0.15, 
0.36), but we judged the evidence to be very low in quality due to early termination of the trials, missing data 
and possible selective reporting from the other trials. No significant effects were observed on any of the 
subscales, including psychological well-being (SMD -0.02 95% CI -0.28, 0.24) or family relationships (SMD 
0.01, 95% CI -0.25, 0.28). Since only observed case S-QoL data were reported, we imputed missing data using 
Strategy 1 from Ebrahim and colleagues (13). This reduced the overall effect from 0.11 to 0.06 (95% CI -0.14, 
0.27). Long-term quality of life data from two RCTs (32, 45) remains unpublished.  
 
An analysis of data from 3 RCTs (1 adolescent; 2 adult) covering a 6-12 week period (30, 31, 40) found 
quetiapine IR had a small-moderate benefit on functioning as assessed by a combination of Children’s Global 
Assessment Scale (CGAS) data and Personal and Social Performance (PSP) data (SMD 0.39, 95% CI 0.18, 
0.60). GAF data was also reported, but unlike the PSP this assesses symptom severity as well as functioning. 
After imputing missing PSP data using Strategy 1, the effect size was small (SMD 0.28, 95% CI 0.09, 0.46). 
One study found no benefit of 12 months of quetiapine IR maintenance treatment over placebo in relation to 
employment status.(45) Overall the functioning and employment data were very low in quality due to selective 
reporting, early termination of studies, imprecision and missing data. High quality evidence from 11 trials 
suggested quetiapine IR had a marginal effect on rates of early discontinuation over a 2-6 week period (NNT 21, 
95 CI 10, 333H).  
 
Safety outcomes (Table 3, Figures 4-6)  
There was low quality evidence that quetiapine IR was associated with a small to moderate increased risk of 
non-serious adverse effects over the short-term (NNH  11, 95% CI 8, 22). There was no evidence of 
extrapyramidal side-effects, and no evidence of an increased risk of serious adverse events. Moderate quality 
evidence suggested no need for additional antiparkinson medication in quetiapine-treated participants over the 
short-term, but longer-term data was not reported.  
 
Data from 12 trials suggested quetiapine IR had a moderate to large effect on weight-gain over 2-12 weeks 
(SMD 0.64, 95% CI 0.43, 0.85). Participants gained an extra 1.75kg (95% CI 1.10kg, 2.40kg) on average 
(~4lbs), but we rated the evidence as very low quality because of non-reporting of variance parameters in 7 out 
of 12 studies, high rates of drop-out, and high heterogeneity. Moderate quality evidence suggested around 12% 
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of quetiapine-treated participants experienced a clinically significant increase in weight over 2-12 weeks, 
compared to 4% of those taking placebo (NNH 13, 95% CI 9, 23) and 35% reported sedation or somnolence as 
an adverse effect, compared to 6% of those taking placebo (NNH 9, 95% CI 7, 13). Details on additional safety 
outcomes and forest-plots are reported in sections I & K in the supplementary file. 
  
Discussion 
 
Main findings 
Using published and unpublished data, the average change in PANSS total scores attributable to quetiapine IR 
over a 2-12 week period was small. Although the 95% confidence intervals excluded the minimum clinically 
important difference of 11-15 points, it should be noted that few treatments for psychosis reach this threshold 
(19). Furthermore, as study duration increased, so did the effect size. Marginal advantages were observed at 2 
weeks, whereas moderate effects that approached the threshold for change of at least minimal clinical 
importance were observed in two as yet unpublished 12-week trials. On the other hand, the overall effect size 
was smaller if we assumed the substantial number of participants who left early would have had the same degree 
of change as placebo-treated participants who stayed. There was no evidence to suggest that drug-attributable 
benefits have been underestimated because of severe rates of drop-out in the older studies. Approximately 21 
people needed to take quetiapine IR for one to experience much improvement, defined in accordance with recent 
recommendations as ≥50% reduction in PANSS total scores (27). 
 
Null to small effects were observed for depression and negative symptoms, respectively. Although moderate 
effects on positive symptoms were observed in the two unpublished 12-week trials, the pooled effect over 2-12 
weeks was small. The two 12-week trials also reported small to moderate effects on functioning but found no 
difference between quetiapine IR and placebo on participant-reported quality of life. Quetiapine IR caused 
weight-gain and sedation, but did not lead to extrapyramidal side-effects. Although there was no evidence of 
increased serious adverse effects, the evidence was very low quality due to imprecision and incomplete 
reporting. 
 
We found some evidence that estimates of clinically significant response derived from more recent trials were 
smaller in magnitude than older trials, which is consistent with results from other antipsychotic meta-analyses 
(4, 46), although no relationship between publication year and total symptoms was observed. It remains unclear 
whether reduced antipsychotic response in recent, large multisite trials with multiple treatment arms reflects a 
change in the characteristics of participants taking part, improvements in study quality or reporting, increased 
variability due to an increasing number of sites, (47) or better masking of treatment allocation due to reduced 
expectation of receiving placebo in such trials. (48)  
 
Older reviews of quetiapine IR have reported effect sizes of  around 0.4 when compared to placebo (3, 4, 19), 
and NNTs of around 10 to 11. (3, 4) However most of the trials available at the time had severe rates of drop-out 
and examined quetiapine IR as the target drug for regulatory approval, rather than as a control for other 
preparations. Previous reviews have not been able to account for selective reporting in relation to response rates, 
examine the impact of changing assumptions about missing data on estimates, or consider the clinical 
significance of the quetiapine IR-attributable change. A more recent review pooled 4-12 week outcome data for 
quetiapine IR with outcome data for the more recent ‘extended release’ version of quetiapine (quetiapine XR) 
and reported an overall moderate effect size of 0.44 (19). Since XR was judged by its manufacturer to be 
sufficiently novel to warrant a separate patent application and significantly greater cost, our a priori view was 
that pooling the XR and IR data would give an inaccurate appraisal of both formulations. In relation to duration, 
we planned to include 2-week quetiapine IR data in our review because this was the approach favoured by 
preceding reviews which were available at the time of protocol writing (4). We adhered to this decision because 
several prescribing guidelines recommend a minimum 2-week trial and evidence on prescribing practices 
suggests psychiatrists normally wait only 3 to 3.5 weeks before switching to another antipsychotic because of 
non-response. (49) Nonetheless, it is important to consider that overall efficacy was positively associated with 
trial duration in our review, and may have been larger still had we included quetiapine XR data. Our data might 
help explain why a recent meta-analysis found that quetiapine IR was significantly less effective at reducing 
positive symptoms than first generation antipsychotics (9 RCTs).(17) In the unpublished Study 15,(32) 
therapeutic dose quetiapine IR was significantly less effective than haloperidol in preventing relapse.  
 
Missing data was high in the included trials. In order to reduce it, trial researchers should continue to assess 
participants who stop treatment early, as this will inform realistic estimates of likely outcome had they stayed, 
both in relation to efficacy and adverse effects. Since many early studies of other second-generation 
antipsychotics also suffered from severe attrition, (6) the robustness of their effects to changing assumptions 
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about missing data may also need to be examined. Although meta-regression has been used to examine the 
relationship between drop-out and effect size, (19) such analyses are inevitably limited by the fact that very few 
trials have low rates of missing data.(6) Application of the Ebrahim approach (13) to this data would help 
prescribers and patients appreciate the extent of uncertainty in estimates of antipsychotic benefits and costs.  
 
In addition to attrition bias, the proper assessment of both drug and non-drug treatments for psychosis continues 
to be limited by incomplete and selective reporting of outcomes, low external validity and non-publication of 
negative trials (8). Indeed, a recent meta-analysis found the median effect of currently available antipsychotics 
over placebo fell from moderate to small after adjusting for the tendency for small studies to report larger effects 
(19), and selective reporting bias is a particular concern when, as documented by Spielmans and Parry (35) and 
others, it biases our understanding of the severity of adverse effects.  
 
Limitations 
We took advantage of several important developments in methodology which were published after we registered 
our protocol (13, 20, 28). Post hoc changes do raise a risk of bias, but we had to balance this against taking the 
opportunity to increase the quality, robustness and usefulness of our estimates, and we hope we have provided 
enough information for readers to judge the merit of these decisions. 
 
Our claim that 11-15 points is required for minimal clinical improvement might be controversial, not least 
because few treatments achieve such change in psychosis (19). However we note the evidence supporting this 
minimum threshold is now quite consistent across different populations (10-12) and we demonstrated that 
quetiapine trial researchers only designed their trials to be able to detect, with adequate power, differences of 
approximately 12 points. Although it has been argued that small benefits might have value at a public health 
level, (4) there is clearly a need for further debate on this issue. As with non-inferiority and equivalence trials, 
(34) researchers planning superiority trials might consider stating explicitly, in advance, what they believe 
constitutes a minimal important difference on continuous outcomes. Although this can be inferred from power 
calculations, it needs to be stated explicitly.  
 
We were unable to access the full clinical study reports (CSR) for each trial, which is problematic given a recent 
study found a much better quality of reporting in these documents, when compared to registry reports or peer-
reviewed publications (50). Although we have acquired a large amount of previously unpublished data, access to 
the CSRs would have raised the quality of many of the outcomes, in particular the assessments of mean weight 
gain and response rates. Acquiring unpublished data was challenging, and we doubt we would have been 
successful had a public debate on publication bias in clinical trials not been taking place at the time. This is an 
unsatisfactory and unsustainable situation, and a change in the law is clearly required to ensure that “all trials 
past and present [are] registered, and the full methods and the results reported” (Alltrials campaign, 2012).”  
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Table 1 Included studies and Cochrane risk of bias ratings  
 
 Year 
published / 
completed 
Primary 
publication 
available? 
Clinical 
study 
report 
synopsis or 
extract 
available? 
Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Performance 
bias (blinding 
of 
participants 
and 
personnel) 
Detection 
bias 
(blinding of 
assessments) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Other bias 
(not 
including 
financial 
conflict of 
interest of 
sponsor or 
researcher) 
 
Arvanitis 1997 Yes (38) Yesa Unclear Unclear Unclear Unclear High Unclear High 
Small 1997 Yes (41) Yesa Low Unclear Unclear Unclear High Unclear High 
Borison 1996 Yes (42) Yesa Unclear Unclear Unclear Unclear High High High 
Kahn 2007 Yes (43) Yes Unclear Unclear Unclear Unclear High High Unclear 
Canuso 2009 Yes (37) Yesb Low Low Unclear Unclear Low Unclear Unclear 
Potkin 2006 Yes (36) No Low Low Unclear Unclear Low High Unclear 
Chen 2010 Yes (45) No Low Low Unclear Unclear High High High 
Lindenmayer 2008 Yes (39) Yes Unclear Unclear Unclear Unclear High High Unclear 
Cutler 2010 Yes (44) Yes Unclear Unclear Unclear Unclear High High Unclear 
Hough 2011 Yes (51) Yes Low Low Unclear High Low High Unclear 
Chapel 2009 Yes (52) No Unclear Unclear Unclear High Unclear High Unclear 
Findling 2007 Yes (40) Yes Low Low Unclear Unclear High Low Low 
Study 
11915A 
2009 No Yes (30) Unclear Unclear Unclear  Unclear High High High 
Study 
11916A 
2009 No Yes (31) Unclear Unclear Unclear Unclear High High High 
Study 15 1995 No Partially 
(32) 
Unclear Unclear Low Low High High High 
a Astrazeneca supplied extract; b Pfizer supplied extract;  Note: see supplementary file for detailed ratings for each reviewer, and for ratings from published reviews (where 
available). 
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Table 2 Primary efficacy outcomes 
 
Outcome Time-point 
(weeks) 
No of 
included 
studies 
Que  
N events / 
N  
Pla N 
events / N 
Hedges’s g 
(95% CI) 
Mean 
difference 
(95% CI)   
Risk ratio 
(95% CI) 
Absolute 
difference 
(95% CI) 
NNTB/H 
(95% CI) 
Heterogeneity 
for g or RR:  
I2; Chi2 (p-
value) 
Quality 
(GRADE) 
Overall symptoms (mean 
change in PANSS total) based 
on LOCF or MMRM 
2-12 11 1346 912 -0.33  
(-0.44, -0.21) 
-6.44 (-8.89, -
4.00) 
- - - 47%; 18.9 
(p=0.040)  
Moderate-
high 
Overall symptoms (mean 
change in PANSS total) using 
Strategy 1 imputations. 
2-12 11 1373 931 -0.23 (-0.35, -
0.11) 
-4.25 (-6.46, -
2.04) 
- - - 52%; 20.7 
(p=0.023) 
 
Overall symptoms (mean 
change in PANSS total) using 
Strategy 2 imputations 
2-12 11 1373 931 -0.15 (-0.30, 
0.01) 
-2.66 (-5.46, 
0.15) 
- - - 70%; 32.9 
(p<0.001) 
 
Significant improvement (≥50% 
reduction in PANSS / BPRS) 
based on LOCF 
2-12 11 1126 / 
1375 
816 / 933 - - 0.95 (0.91, 
0.98) 
-0.047 (-0.016, -
0.016) 
21B (13B, 
63B)  
43%; 17.5 
(p=0.070) 
Low -
moderate 
Shaded rows indicates result statistically significant at p<0.05  
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Table 3 Main safety outcomes 
 
Outcome (definition, 
imputation strategy) 
Time-point 
(weeks) 
No of 
included 
studies 
Que  
N events 
/ N  
Pla N 
events / N 
Hedges’s g 
(95% CI) 
Mean difference 
(95% CI)   
Risk ratio 
(95% CI) 
Absolute 
difference 
(95% CI) 
NNTB/H 
(95% CI) 
Heterogeneity 
for g or RR:  
I2; Chi2 (p-value) 
Quality 
(GRADE) 
Serious adverse events 2-12 8 50/851 45/658 - - 0.94 (0.64, 
1.39) 
-0.001 (-0.023, 
0.021) 
1000B 
(44B, 48H) 
0%; 3.3 (p=0.885) Very low 
Any adverse event 2-12 9 754/1112 438/756 - - 1.14 (1.06, 
1.22) 
0.089 (0.045, 
0.134) 
11H (22H, 
8H) 
0%; 6.6 (p=0.583) Low 
Simpson-Angus Scale 
(worsening) 
6 7 128/869 83/596 - - 0.97 (0.73, 
1.29) 
0.007 (-0.033, 
0.047) 
143H (30B, 
21H) 
15%; 7 (p=0.317) Low 
Abnormal Involuntary 
Movement Scale 
(worsening) 
6 4 88/534 56/265 - - 0.694 (0.521, 
0.924) 
-0.047 (-0.130, 
0.037) 
21B (8B, 
27H) 
0%; 2.6 (0.460) Low 
Barnes Akathesia Scale 
(worsening) 
2-6 7 67/973 49/643 - - 0.866 (0.609, 
1.234) 
-0.005 (-0.030, 
0.020) 
200B (33B, 
50H) 
0%l 3.5 (p=0.745) Low 
Needing medication for 
extra-pyramidal side-
effects 
2-6 9 97/1071 65/698 - - 0.838 (0.597, 
1.176) 
0.004 (-0.025, 
0.032) 
250H (40B, 
31H) 
12%; 9.1 
(p=0.334) 
Moderate 
Mean weight change 2-12 12 1410 948 0.640 (0.428, 
0.852) 
1.753kg (1.104, 
2.402) 
- - - 83%; 65.4 
(p<0.001) 
Very low 
Significant weight-gain 
(≥7% or recorded as 
adverse effect) 
2-12 10 140/1220 32/863 - - 2.988 (2.048, 
4.362) 
0.076 (0.044, 
0.109) 
13H (23H, 
9H) 
0%; 6.9 (p=0.648) Moderate 
Sedation or somnolence 2-12 12 247/1419 57/958 - - 2.818 (1.963, 
4.047) 
0.115 (0.078, 
0.151) 
9H (7H, 
13H) 
31%; 16.1 
(p=0.138) 
Moderate 
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Outcome (definition, 
imputation strategy) 
Time-point 
(weeks) 
No of 
included 
studies 
Que  
N events 
/ N  
Pla N 
events / N 
Hedges’s g 
(95% CI) 
Mean difference 
(95% CI)   
Risk ratio 
(95% CI) 
Absolute 
difference 
(95% CI) 
NNTB/H 
(95% CI) 
Heterogeneity 
for g or RR:  
I2; Chi2 (p-value) 
Quality 
(GRADE) 
Leaving early due to 
adverse effects 
2-12 11 97/1263 74/885 -  1.009 (0.753, 
1.351) 
0.010 (-0.010, 
0.031) 
100H 
(100B, 
32H) 
0%; 9.4 (p=0.495) Moderate  
 
Shaded rows indicates result statistically significant at p<0.05; *indicates at least moderate heterogeneity (I2 ≥ 40%); bold text indicates primary outcome 
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Figure 1 PRISMA Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Number of records 
identified through 
database searching: 
 
 
535 
 
 
 
Number of records 
identified through 
other sources: 58 
       
       
       
  
Number of records 
after duplicates 
removed: 461 
 
Number of records 
excluded on basis of 
title: 272 
       
       
       
  
Number of records 
screened (abstract / 
description): 189 
 
Number of records 
excluded: 70 
       
       
  
Number of full-text 
reports screened for 
eligibility: 119 
 
Number of full-text 
reports excluded: 104 
  
 
  
No placebo only 
group: 32 
     
Observational / not 
RCT: 23 
  
Number of studies 
included in review: 15  
No quetiapine IR 
group: 6 
     Not schizophrenia: 11 
     Not double-blind: 20 
     Never performed: 6 
     Non-optimal dose: 1 
     
Duplicate, secondary 
publication or 
otherwise not 
relevant: 5 
       
     
Number of untraced 
full-text reports: 0 
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Model Study name Statistics for each study Sample size Difference in 
means and 95%  CI
Difference Lower Upper 
in means limit limit p-Value Drug Placebo Total
Borison, 1996, 6 weeks* -9.231 -19.423 0.961 0.076 53 53 106
11915A, 12 weeks -8.900 -13.588 -4.212 0.000 76 68 144
Small, 1997, 6 weeks* -11.969 -18.899 -5.039 0.001 94 94 188
Arvanitis, 1997, 6 weeks* -14.197 -21.350 -7.044 0.000 155 51 206
Cutler, 2008, 6 weeks -2.900 -8.168 2.368 0.281 109 111 220
Findling, 2012, 6 weeks -8.730 -14.839 -2.622 0.005 147 73 220
Potkin, 2006, 2 weeks -0.300 -5.397 4.797 0.908 156 71 227
11916A, 12 weeks -7.200 -11.129 -3.271 0.000 115 118 233
Kahn, 2007, 6 weeks -7.800 -14.590 -1.010 0.024 119 115 234
Canuso, 2009, 2 weeks -2.900 -7.435 1.635 0.210 157 80 237
Lindenmayer, 2008, 6 weeks* -2.588 -8.065 2.889 0.354 165 78 243
Fixed -6.115 -7.770 -4.460 0.000 1346 912 2258
Random -6.445 -8.894 -3.996 0.000 1346 912 2258
-25.00 -12.50 0.00 12.50 25.00
Favours QUE Favours PLA
Figure 2 Mean change in PANSS total scores or equivalent, using mostly original LOCF estimates to impute missing data (*indicates severe attrition, ≥50%) 
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Model Study name Statistics for each study Events Sample size Risk ratio and 95%  CI
Risk Lower Upper 
ratio limit limit p-Value Drug Placebo Total Drug Placebo Total
Borison, 1996, 6 weeks, 50% PANSS - F* 0.912 0.771 1.080 0.286 43 48 91 54 55 109
11915A 12 weeks 50% PANSS - F 0.895 0.805 0.994 0.039 65 65 130 76 68 144
Small, 1997, 6 weeks, 50% PANSS - F* 0.827 0.689 0.992 0.040 62 75 137 96 96 192
Arvanitis, 1997, 6 weeks 60% BPRS* 0.877 0.814 0.945 0.001 135 50 185 157 51 208
Findling, 2012, 6 weeks 50% PANSS - F 0.869 0.716 1.054 0.155 91 52 143 147 73 220
Potkin, 2006, 2 weeks, 50% PANSS - F 0.986 0.845 1.151 0.859 118 56 174 156 73 229
Cutler 2010, 6 weeks 50% PANSS 1.000 0.959 1.042 0.992 113 114 227 116 117 233
11916A 12 weeks 50% PANSS - F 0.986 0.892 1.091 0.787 99 103 202 115 118 233
Canuso 2009 50% PANSS 0.976 0.860 1.108 0.705 128 66 194 159 80 239
Kahn 2007, 50% PANSS 0.932 0.841 1.032 0.177 102 105 207 123 118 241
Lindenmayer 2008, 6 weeks 50% PANSS* 0.989 0.947 1.033 0.633 170 82 252 176 84 260
Fixed 0.965 0.943 0.988 0.004 1126 816 1942 1375 933 2308
Random 0.948 0.913 0.984 0.005 1126 816 1942 1375 933 2308
0.5 1 2
Favours QUE Favours PLA
Figure 3. Relative risk of not achieving at least 50% reduction in PANSS total scores or equivalent, based on mostly LOCF data (F = estimated using Furukawa 
method; *indicates severe attrition ≥50%) 
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Model Study name Statistics for each study Sample size Difference in 
means and 95%  CI
Difference Lower Upper 
in means limit limit p-Value Drug Placebo Total
Hough, 2011, 2-WK SD imputed 1.400 0.056 2.744 0.041 43 22 65
Borison, 1996, 6-WK* SD imputed 5.000 3.999 6.001 0.000 54 55 109
11915A, 12-WK, SD imputed 1.600 0.731 2.469 0.000 76 68 144
Small, 1997, 6-WK* SD imputed 1.900 1.146 2.654 0.000 96 96 192
Arvanitis, 1997, 6-WK* SD imputed 3.100 2.282 3.918 0.000 157 51 208
Cutler, 2010, 6-WK, 1.080 -0.353 2.513 0.140 108 107 215
Findling, 2012, 6-WK 1.800 1.067 2.533 0.000 147 75 222
Potkin 2006, 2-WK 0.500 0.019 0.981 0.042 156 73 229
11916A, 12-WK, SD imputed 1.900 1.217 2.583 0.000 115 119 234
Canuso 2009, 2-WK 0.600 0.208 0.992 0.003 159 80 239
Kahn 2007, 6-WK 0.920 0.194 1.646 0.013 123 118 241
Lindenmayer, 2008, 6-WK* 1.490 0.601 2.379 0.001 176 84 260
Fixed 1.361 1.160 1.563 0.000 1410 948 2358
Random 1.753 1.104 2.402 0.000 1410 948 2358
-4.00 -2.00 0.00 2.00 4.00
Favours QUE Favours PLA
 
Figure 4. Mean weight-gain (kg; *indicates severe attrition, ≥50%) 
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Model Study name Statistics for each study Events Sample size Risk ratio and 95%  CI
Risk Lower Upper 
ratio limit limit p-Value Drug Placebo Total Drug Placebo Total
Borison, 1996, 6-WK* 7.130 1.701 29.889 0.007 14 2 16 54 55 109
11915A, 12-WK 11.649 0.668 203.016 0.092 6 0 6 76 68 144
Small, 1997, 6-WK* 4.800 1.911 12.057 0.001 24 5 29 96 96 192
Arvanitis, 1997, 6-WK* 2.166 0.671 6.989 0.196 20 3 23 157 51 208
Findling, 2012, 6-WK 3.912 1.213 12.610 0.022 23 3 26 147 75 222
Cutler, 2010, 6-WK 2.185 0.860 5.553 0.100 13 6 19 116 117 233
11916A, 12-WK 8.207 1.043 64.589 0.046 8 1 9 116 119 235
Canuso 2009, 2-WK 2.516 0.299 21.173 0.396 5 1 6 159 80 239
Kahn 2007, 6-WK 1.812 0.841 3.904 0.129 17 9 26 123 118 241
Lindenmayer, 2008, 6-WK* 2.386 0.535 10.650 0.254 10 2 12 176 84 260
Fixed 2.988 2.048 4.362 0.000 140 32 172 1220 863 2083
Random 2.988 2.048 4.362 0.000 140 32 172 1220 863 2083
0.01 0.1 1 10 100
Favours QUE Favours PLA
Figure 5. Relative risk of clinically significant weight-gain (normally ≥7% increase) (*indicates severe attrition, ≥50%) 
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Model Study name Statistics for each study Events Sample size Risk ratio and 95%  CI
Risk Lower Upper 
ratio limit limit p-Value Drug Placebo Total Drug Placebo Total
Hough, 2011, 2-WK 1.919 0.723 5.091 0.191 15 4 19 43 22 65
Borison, 1996, 6-WK* 5.347 1.965 14.552 0.001 21 4 25 54 55 109
11916A, 12-WK 14.316 1.950 105.107 0.009 16 1 17 76 68 144
Small, 1997, 6-WK* 1.714 0.945 3.109 0.076 24 14 38 96 96 192
Arvanitis, 1997, 6-WK* 1.137 0.392 3.299 0.813 14 4 18 157 51 208
Findling, 2012, 6-WK 4.286 1.770 10.379 0.001 42 5 47 147 75 222
Potkin 2006, 2-WK 3.744 0.884 15.855 0.073 16 2 18 156 73 229
Cutler, 2010, 6-WK 2.292 1.184 4.440 0.014 25 11 36 116 117 233
11915A, 12-WK 12.310 1.627 93.162 0.015 12 1 13 116 119 235
Canuso 2009, 2-WK 9.560 1.303 70.134 0.026 19 1 20 159 80 239
Kahn 2007, 6-WK 4.797 1.073 21.434 0.040 10 2 12 123 118 241
Lindenmayer, 2008, 6-WK*1.969 0.951 4.074 0.068 33 8 41 176 84 260
Fixed 2.581 1.953 3.410 0.000 247 57 304 1419 958 2377
Random 2.818 1.963 4.047 0.000 247 57 304 1419 958 2377
0.01 0.1 1 10 100
Favours QUE Favours PLA
Figure 6. Relative risk of somnolence or sedation (*indicates severe attrition, ≥50%) 
 
  
 
 
 
